Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
By Bronwyn Mixter
Dec. 10 — The FDA Dec. 9 said it is alerting drug compounders that certain lots of baclofen active pharmaceutical ingredient (API) manufactured by China-based Taizhou Xinyou Pharmaceutical & Chemical Co. may be at risk for contamination with particulates and shouldn't be used to compound sterile injectable drugs.
Taizhou manufactures APIs for repackagers and distributors, some of which sell these products to compounding facilities in the U.S., the Food and Drug Administration said. The agency said it contacted Taizhou through its U.S. agent, and the company confirmed that, due to the level of controls in the manufacturing process, the baclofen API it manufactures isn't suitable for use in injectable drugs.
The FDA said it recommends that no baclofen API from Taizhou be used to manufacture or compound any injectable drugs. Baclofen is a muscle relaxant.
Based on available information, the affected API may potentially pose serious safety risks for U.S. patients who use or receive injectable drug products compounded with the affected baclofen, especially when administered directly into the spinal column, the FDA said.
The agency also said there is a potential risk that the baclofen API may be contaminated by endotoxin or microorganisms.
The FDA said it is continuing to investigate this incident. Adverse events associated with the affected baclofen API should be reported to the FDA's MedWatch Adverse Event Reporting program, the agency said.
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)